129 related articles for article (PubMed ID: 29212486)
41. Abdominal aortic aneurysmal and endovascular device infection with iliopsoas abscess caused by Mycobacterium bovis as a complication of intravesical bacillus Calmette-Guérin therapy.
Mizoguchi H; Iida O; Dohi T; Tomoda K; Kimura H; Inoue K; Iwata T; Tei K; Miura T
Ann Vasc Surg; 2013 Nov; 27(8):1186.e1-5. PubMed ID: 23972639
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study.
Soria F; Milla P; Fiorito C; Pisano F; Sogni F; Di Marco M; Pagliarulo V; Dosio F; Gontero P
World J Urol; 2016 Feb; 34(2):189-95. PubMed ID: 26026818
[TBL] [Abstract][Full Text] [Related]
43. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy.
Barlow L; McKiernan J; Sawczuk I; Benson M
BJU Int; 2009 Oct; 104(8):1098-102. PubMed ID: 19389012
[TBL] [Abstract][Full Text] [Related]
44. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
Turker P; Turkeri L
Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
[TBL] [Abstract][Full Text] [Related]
45. BCG pyelonephritis following intravesical therapy for transitional cell carcinoma.
Garcia JE; Thiel DD; Broderick GA
Can J Urol; 2007 Apr; 14(2):3523-5. PubMed ID: 17466161
[TBL] [Abstract][Full Text] [Related]
46. [Prevention of topic toxicity of BCG with single-dose prulifloxacin. Preliminary results of a randomized pilot study].
Serretta V; Ruggirello A; Giaimo R; Sommatino F; Billone V; Allegro R; Melloni D
Urologia; 2010; 77(4):240-7. PubMed ID: 21234866
[TBL] [Abstract][Full Text] [Related]
47. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
[TBL] [Abstract][Full Text] [Related]
48. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer.
Chen CH; Yang HJ; Shun CT; Huang CY; Huang KH; Yu HJ; Pu YS
Urol Oncol; 2012; 30(4):421-7. PubMed ID: 20870427
[TBL] [Abstract][Full Text] [Related]
49. A case of disseminated Mycobacterium bovis 2 years post-intravesicular Bacillus Calmette-Guérin therapy for superficial urinary bladder cancer.
Robinson ARL; Radhakrishnan R; Horvath R; Pandey S
Intern Med J; 2017 Jul; 47(7):820-823. PubMed ID: 28677313
[TBL] [Abstract][Full Text] [Related]
50. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.
Gontero P; Bohle A; Malmstrom PU; O'Donnell MA; Oderda M; Sylvester R; Witjes F
Eur Urol; 2010 Mar; 57(3):410-29. PubMed ID: 19969411
[TBL] [Abstract][Full Text] [Related]
51. Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Guérin relapsing non-muscle-invasive bladder cancer.
Matsumoto K; Kikuchi E; Shirakawa H; Hayakawa N; Tanaka N; Ninomiya A; Miyajima A; Nakamura S; Oya M
BJU Int; 2012 Dec; 110(11 Pt B):E508-13. PubMed ID: 22574662
[TBL] [Abstract][Full Text] [Related]
52. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
53. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
Evans CP
Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
[No Abstract] [Full Text] [Related]
54. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
Barlow LJ; McKiernan JM; Benson MC
J Urol; 2013 Mar; 189(3):834-9. PubMed ID: 23123371
[TBL] [Abstract][Full Text] [Related]
55. Valrubicin in refractory non-muscle invasive bladder cancer.
Sharma P; Zargar-Shoshtari K; Sexton WJ
Expert Rev Anticancer Ther; 2015; 15(12):1379-87. PubMed ID: 26569509
[TBL] [Abstract][Full Text] [Related]
56. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.
Ajili F; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613
[TBL] [Abstract][Full Text] [Related]
57. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.
Kamat AM; Colombel M; Sundi D; Lamm D; Boehle A; Brausi M; Buckley R; Persad R; Palou J; Soloway M; Witjes JA
Nat Rev Urol; 2017 Apr; 14(4):244-255. PubMed ID: 28248951
[TBL] [Abstract][Full Text] [Related]
58. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
59. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
[TBL] [Abstract][Full Text] [Related]
60. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.
Nepple KG; Lightfoot AJ; Rosevear HM; O'Donnell MA; Lamm DL;
J Urol; 2010 Nov; 184(5):1915-9. PubMed ID: 20846688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
